DNMT1-maintained hypermethylation of Krüppel-like factor 5 involves in the progression of clear cell renal cell carcinoma.

DNMT1-maintained hypermethylation of Krüppel-like factor 5 involves in the progression of clear cell renal cell carcinoma.
复制标题

DNMT1 维持的 Kruppel 样因子 5 的高甲基化参与透明细胞肾细胞癌的进展

DOI:
10.1038/cddis.2017.323
复制
发表时间:
2017-07-27
影响因子:
9
通讯作者:
Zhao KW
Zhao KW
中科院分区:
生物学1区
文献类型:
--
作者:
Fu RJ;He W;Wang XB;Li L;Zhao HB;Liu XY;Pang Z;Chen GQ;Huang L;Zhao KW

文献摘要

参考文献

被引文献

相似文献

透明细胞肾细胞癌(ccRCC)是肾细胞癌(RCC)的主要亚型,对常规放疗和化疗具有抗性。因此,寻找有效的治疗靶点和药物是一个挑战。转录因子Krüppel样因子5(KLF 5)在不同类型的肿瘤中发挥不同的功能。通过分析癌症基因组图谱(TCGA)数据集的队列,我们发现在ccRCC患者中KLF 5表达受到抑制,并且较高水平的KLF 5表达与较好的预后结果相关。我们的进一步研究表明,KLF 5基因组位点在近端外显子4处高度甲基化,通过ShRNA或甲基化抑制剂5-Aza-CdR抑制DNA甲基转移酶1(DNMT 1)表达可以恢复KLF 5的表达。同时,肾细胞癌组织中KLF 5和DNMT 1的表达呈负相关。异位KLF 5表达抑制体外ccRCC细胞增殖和迁移/侵袭,并减少体内异种移植物生长和转移。此外,作为DNMT抑制剂的化疗药物5-Aza-CdR可以诱导KLF 5表达,抑制ccRCC细胞生长,而KLF 5的敲低消除了5-Aza-CdR诱导的生长抑制。总的来说,我们的数据表明KLF 5作为肿瘤抑制因子抑制ccRCC生长,并突出了5-Aza-CdR释放KLF 5表达作为治疗ccRCC的治疗方式的潜力。
Clear cell renal cell carcinoma (ccRCC) is the major subtype of renal cell carcinoma (RCC) that is resistant to conventional radiation and chemotherapy. It is a challenge to explore effective therapeutic targets and drugs for this kind of cancer. Transcription factor Krüppel-like factor 5 (KLF5) exerts diverse functions in various tumor types. By analyzing cohorts of the Cancer Genome Atlas (TCGA) data sets, we find that KLF5 expression is suppressed in ccRCC patients and higher level of KLF5 expression is associated with better prognostic outcome. Our further investigations demonstrate that KLF5 genomic loci are hypermethylated at proximal exon 4 and suppression of DNA methyltransferase 1 (DNMT1) expression by ShRNAs or a methylation inhibitor 5-Aza-CdR can recover KLF5 expression. Meanwhile, there is a negative correlation between expressions of KLF5 and DNMT1 in ccRCC tissues. Ectopic KLF5 expression inhibits ccRCC cell proliferation and migration/invasion in vitro and decreases xenograft growth and metastasis in vivo. Moreover, 5-Aza-CdR, a chemotherapy drug as DNMTs’ inhibitor that can induce KLF5 expression, suppresses ccRCC cell growth, while knockdown of KLF5 abolishes 5-Aza-CdR-induced growth inhibition. Collectively, our data demonstrate that KLF5 inhibits ccRCC growth as a tumor suppressor and highlight the potential of 5-Aza-CdR to release KLF5 expression as a therapeutic modality for the treatment of ccRCC.
在前列腺癌细胞中,KLF5 乙酰化的中断可将其功能从肿瘤抑制因子转变为肿瘤促进因子。
DOI: 10.1002/ijc.29028
发表时间: 2015-02-01
影响因子: 6.4
作者:
Li, Xin;Zhang, Baotong;Wu, Qiao;Ci, Xinpei;Zhao, Ranran;Zhang, Zhiqian;Xia, Siyuan;Su, Dan;Chen, Jie;Ma, Gui;Fu, Liya;Dong, Jin-Tang
通讯作者: Dong, Jin-Tang
DOI: 10.1016/j.leukres.2011.03.010
发表时间: 2011-07-01
期刊: LEUKEMIA RESEARCH
影响因子: 2.7
作者:
Humbert, Magali;Halter, Veronika;Tschan, Mario P.
通讯作者: Tschan, Mario P.
DOI: 10.1074/jbc.m506183200
发表时间: 2005-12-16
影响因子: 4.8
作者:
Chen, CS;Sun, XD;Dong, JT
通讯作者: Dong, JT
DOI: 10.1074/jbc.m109.007096
发表时间: 2009-07-03
影响因子: 4.8
作者:
Guo, Peng;Zhao, Ke-Wen;Dong, Jin-Tang
通讯作者: Dong, Jin-Tang
DOI: 10.1038/bjp.2008.17
发表时间: 2008-04-01
影响因子: 7.3
作者:
Hagiwara, H.;Sato, H.;Yano, T.
通讯作者: Yano, T.